MicroRNAs and Long Non-coding RNAs in the Pathophysiological Processes of Diabetic Cardiomyopathy: Emerging Biomarkers and Potential Therapeutics

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2021 Feb 28

PMID 33639953

Citations 44

Authors

Daniel Jakubik

Alex Fitas

Ceren Eyileten

Joanna Jarosz-Popek

Anna Nowak

Pamela Czajka

Zofia Wicik

Harald Sourij

Jolanta M Siller-Matula

Salvatore De Rosa

Marek Postula

Affiliations

Soon will be listed here.

Abstract

The epidemic of diabetes mellitus (DM) necessitates the development of novel therapeutic and preventative strategies to attenuate complications of this debilitating disease. Diabetic cardiomyopathy (DCM) is a frequent disorder affecting individuals diagnosed with DM characterized by left ventricular hypertrophy, diastolic and systolic dysfunction and myocardial fibrosis in the absence of other heart diseases. Progression of DCM is associated with impaired cardiac insulin metabolic signaling, increased oxidative stress, impaired mitochondrial and cardiomyocyte calcium metabolism, and inflammation. Various non-coding RNAs, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), as well as their target genes are implicated in the complex pathophysiology of DCM. It has been demonstrated that miRNAs and lncRNAs play an important role in maintaining homeostasis through regulation of multiple genes, thus they attract substantial scientific interest as biomarkers for diagnosis, prognosis and as a potential therapeutic strategy in DM complications. This article will review the different miRNAs and lncRNA studied in the context of DM, including type 1 and type 2 diabetes and the contribution of pathophysiological mechanisms including inflammatory response, oxidative stress, apoptosis, hypertrophy and fibrosis to the development of DCM .

Citing Articles

The role of long non-coding RNAs in cardiovascular diseases: A comprehensive review.

Xie X, Huang M, Ma S, Xin Q, Wang Y, Hu L Noncoding RNA Res. 2025; 11:158-187.

PMID: 39896344 PMC: 11783329. DOI: 10.1016/j.ncrna.2024.12.009.

Shenmai Injection Reduces Cardiomyocyte Apoptosis Induced by Doxorubicin through miR-30a/Bcl-2.

Zhang X, Li Y, Lyu S, Jia Q, Zhang J, Liu L Chin J Integr Med. 2025; 31(3):240-250.

PMID: 39809965 DOI: 10.1007/s11655-025-4005-8.

Role of Circulating Biomarkers in Diabetic Cardiomyopathy.

Ianos R, Cozma A, Lucaciu R, Hangan A, Negrean V, Mercea D Biomedicines. 2024; 12(9).

PMID: 39335666 PMC: 11428922. DOI: 10.3390/biomedicines12092153.

Therapeutic potential of finerenone for diabetic cardiomyopathy: focus on the mechanisms.

Wang J, Xue H, He J, Deng L, Tian J, Jiang Y Diabetol Metab Syndr. 2024; 16(1):232.

PMID: 39289758 PMC: 11409712. DOI: 10.1186/s13098-024-01466-x.

Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy.

Galis P, Bartosova L, Farkasova V, Bartekova M, Ferenczyova K, Rajtik T Front Endocrinol (Lausanne). 2024; 15:1451100.

PMID: 39140033 PMC: 11319149. DOI: 10.3389/fendo.2024.1451100.

References

Fink S, Cookson B . Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005; 73(4):1907-16. PMC: 1087413. DOI: 10.1128/IAI.73.4.1907-1916.2005. View

Corsten M, Papageorgiou A, Verhesen W, Carai P, Lindow M, Obad S . MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res. 2012; 111(4):415-25. DOI: 10.1161/CIRCRESAHA.112.267443. View

Diao X, Shen E, Wang X, Hu B . Differentially expressed microRNAs and their target genes in the hearts of streptozotocin-induced diabetic mice. Mol Med Rep. 2011; 4(4):633-40. DOI: 10.3892/mmr.2011.489. View

Tang Q, Len Q, Liu Z, Wang W . Overexpression of miR-22 attenuates oxidative stress injury in diabetic cardiomyopathy via Sirt 1. Cardiovasc Ther. 2017; 36(2). DOI: 10.1111/1755-5922.12318. View

Raut S, Kumar A, Singh G, Nahar U, Sharma V, Mittal A . miR-30c Mediates Upregulation of Cdc42 and Pak1 in Diabetic Cardiomyopathy. Cardiovasc Ther. 2015; 33(3):89-97. DOI: 10.1111/1755-5922.12113. View

Zhang L, Luo X, Chen F, Yuan W, Xiao X, Zhang X . LncRNA SNHG1 regulates cerebrovascular pathologies as a competing endogenous RNA through HIF-1α/VEGF signaling in ischemic stroke. J Cell Biochem. 2018; 119(7):5460-5472. DOI: 10.1002/jcb.26705. View

Ghafouri-Fard S, Shoorei H, Taheri M . Non-coding RNAs are involved in the response to oxidative stress. Biomed Pharmacother. 2020; 127:110228. DOI: 10.1016/j.biopha.2020.110228. View

Rawal S, Nagesh P, Coffey S, van Hout I, Galvin I, Bunton R . Early dysregulation of cardiac-specific microRNA-208a is linked to maladaptive cardiac remodelling in diabetic myocardium. Cardiovasc Diabetol. 2019; 18(1):13. PMC: 6352455. DOI: 10.1186/s12933-019-0814-4. View

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M . MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456(7224):980-4. DOI: 10.1038/nature07511. View

10.

Greco S, Fasanaro P, Castelvecchio S, DAlessandra Y, Arcelli D, Di Donato M . MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes. 2012; 61(6):1633-41. PMC: 3357263. DOI: 10.2337/db11-0952. View

11.

Braga L, Ali H, Secco I, Giacca M . Non-coding RNA therapeutics for cardiac regeneration. Cardiovasc Res. 2020; 117(3):674-693. PMC: 7898953. DOI: 10.1093/cvr/cvaa071. View

12.

Wang L, Wang M, Hu J, Shen W, Hu J, Yao Y . Protective effect of 3H-1, 2-dithiole-3-thione on cellular model of Alzheimer's disease involves Nrf2/ARE signaling pathway. Eur J Pharmacol. 2016; 795:115-123. DOI: 10.1016/j.ejphar.2016.12.013. View

13.

Erener S, Marwaha A, Tan R, Panagiotopoulos C, Kieffer T . Profiling of circulating microRNAs in children with recent onset of type 1 diabetes. JCI Insight. 2017; 2(4):e89656. PMC: 5313074. DOI: 10.1172/jci.insight.89656. View

14.

Hu X, Bai T, Xu Z, Liu Q, Zheng Y, Cai L . Pathophysiological Fundamentals of Diabetic Cardiomyopathy. Compr Physiol. 2017; 7(2):693-711. DOI: 10.1002/cphy.c160021. View

15.

An J, Li P, Li J, Dietz R, Donath S . ARC is a critical cardiomyocyte survival switch in doxorubicin cardiotoxicity. J Mol Med (Berl). 2009; 87(4):401-10. DOI: 10.1007/s00109-008-0434-z. View

16.

Dai B, Li H, Fan J, Zhao Y, Yin Z, Nie X . MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin. Cardiovasc Diabetol. 2018; 17(1):123. PMC: 6122727. DOI: 10.1186/s12933-018-0767-z. View

17.

Wang J, Lv B, Su Y, Wang X, Bu J, Yao L . Exosome-Mediated Transfer of lncRNA HOTTIP Promotes Cisplatin Resistance in Gastric Cancer Cells by Regulating HMGA1/miR-218 Axis. Onco Targets Ther. 2020; 12:11325-11338. PMC: 6930390. DOI: 10.2147/OTT.S231846. View

18.

Zhao Z, Hao W, Meng Q, Du X, Lei S, Xia Z . Long non-coding RNA MALAT1 functions as a mediator in cardioprotective effects of fentanyl in myocardial ischemia-reperfusion injury. Cell Biol Int. 2016; 41(1):62-70. DOI: 10.1002/cbin.10701. View

19.

Barish G, Yu R, Karunasiri M, Ocampo C, Dixon J, Benner C . Bcl-6 and NF-kappaB cistromes mediate opposing regulation of the innate immune response. Genes Dev. 2010; 24(24):2760-5. PMC: 3003193. DOI: 10.1101/gad.1998010. View

20.

Gao L, Liu Y, Guo S, Xiao L, Wu L, Wang Z . LAZ3 protects cardiac remodeling in diabetic cardiomyopathy via regulating miR-21/PPARa signaling. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(10):3322-3338. DOI: 10.1016/j.bbadis.2018.07.019. View